Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOxTROT platform trial in locally advanced operable colon cancer
ISRCTN83842641Phase 3Recruiting
- Sponsor
- University of Leeds
- Start
- Feb 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil, capecitabine, irinotecan, cetuximab and 3 more in colon cancer (7 arms), sponsored by University of Leeds. Primary endpoints: Disease-free survival, Tumour regression grade and 2 more. Started Feb 2022; status: recruiting.
02
Drugs
oxaliplatinfluorouracilcapecitabineirinotecancetuximab
03
Conditions
colon cancer
Beyond the preview
Go deeper on ISRCTN83842641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83842641.